Amino acid solution clinical trials
3 indexed studies · 1 currently recruiting
- RecruitingPHASE3
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
This study looks at treating advanced gut neuroendocrine tumours (NETs) with a medicine called 177Lu-Dotatate. It compares giving the medicine every 8 weeks versus every 16 weeks to see if less frequent doses cause fewer side effects while still working well.
For: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)France · Spain - Active not recruitingPHASE3
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
This study looks at a new type of radiation treatment called PRRT (using Lutetium-177) for certain aggressive bowel and pancreas neuroendocrine tumours. It compares this new treatment with standard care to see if it's more effective, safer, and improves patients' quality of life.
For: Neuroendocrine TumorsUnited States · Australia · China - Active not recruitingPHASE3
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
This study compares a new radiation treatment (177Lu-edotreotide PRRT) with a standard drug (Everolimus) for people with certain types of advanced neuroendocrine tumours that affect the gut or pancreas. It aims to see which treatment works better and is safer.
For: Neuroendocrine TumorsUnited States · Australia · Austria